Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Anthony P. Bihl III

Market Cap

434.67 Million USD

Sector

Healthcare

Website

https://www.bioventus.com

Last Update

2/22/2024, 12:00:00 PM

Description

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally.

Read More

Overview

Value

10

Growth

41

Health

36

Management

27

Analyst Opinion

71

Total

37

All Scores Out Of 100

Best Features

  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • Has a high level of debt
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Dividend could be at risk

Market Peers

BVS

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-30.84%

Revenue Growth (5 Year Average)

-1.58%

Ratings Consensus

Buy

Share Buybacks

-0.81%

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

10

  • Estimated intrinsic-value of 3.53 USD is lower than current price ( 6.81 USD)
  • Free-cashflow-yeild of -0.06% is worse than the market average (4.7%)
  • Margin-of-safety of -30.84% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 3.5 USD

Current Price: 5.1 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-0.06%

PE/Earnings Growth

N/A

Price/Book

1.42x

Growth

Growth Score

41

  • 5 Year Average Earnings growth of 24.54% is higher than the market average (14.48%)
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of -1.58% is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 0.40% is lower than the market average (12.35%)

Revenue Growth

-1.58%

Earnings Growth

24.54%

Cashflow Growth

0.40%

Health

Health Score

36

  • Assets cover liabilities
  • Cashflow is negative
  • Has a high level of debt
  • High financial leverage and base interest rate exposure
  • Requires debt for normal operation to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

0.75

Piostroski Score

5.00

Debt/Equity

1.74x

Current Assets/Liabilities

1.49x

Free Cashflow/Total Debt

0.00x

Debt/Capital

1.60x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 12.82% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

27

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of 3.17% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -3.34% is lower than the market average (15%)

Average Buybacks/Dilution

-0.81%

Recent Buybacks/Dilution

0.23%

5 Year Price Volitility

63.12%

Return On Assets

-0.93%

Return On Capital Employed

3.17%

Return On Equity

-3.34%

Return On Free Cashflow

N/A

Return On Investments

-110.08%

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

71

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Bioventus Inc.

Currency

USD

Beta

0.262962

Vol Avg

746942

Ceo

Mr. Anthony P. Bihl III

Cik

0001665988

Cusip

09075A108

Exchange

NASDAQ Global Select

Full Time Employees

1040

Industry

Medical Devices

Sector

Healthcare

Ipo Date

2021-02-11

Address

4721 Emperor Boulevard

City

Durham

State

NC

Country

US

Zip

27703

Phone

919 474 6700

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies